Evolutionary Double-Bind Strategy Overcomes Therapy Resistance in Prostate Cancer
A novel study led by Trinity College Dublin (TCD) demonstrates how radiation therapy can be used to expose, and then eliminate, therapy-resistant prostate cancer cells by harnessing the body’s natural killer cells. Researchers found this approach may similarly offer hope for treating other forms of therapy-resistant cancer.
Understanding Cancer’s Evolutionary Capacity
Cancer cells are remarkably adept at evolving resistance to therapies, often leading to tumor recurrence, treatment failure, and patient death. Many patients initially respond well to treatment, even achieving complete remission, but resistance frequently develops over time. Scientists are increasingly focused on understanding and exploiting this evolutionary process to improve treatment outcomes.
The “Evolutionary Double-Bind” Strategy
An international team from TCD and the Moffitt Cancer Center in the US has pioneered a landmark “evolutionary double-bind” strategy to overcome treatment resistance in prostate cancer. This approach leverages the way cancers evolve as a vulnerability, rather than a roadblock. The concept, often discussed in oncology, has now been validated through both laboratory experiments and detailed mathematical modeling [1].
As explained by Robert Gatenby from the Moffitt Cancer Center, the strategy is analogous to controlling a rodent population: “You might start by introducing owls, but the rodents can adapt by hiding under bushes. Here, the addition of snakes represents an evolution double bind – rodents trying to escape the owls are vulnerable to the snake and, if they avoid the snakes by staying away from bushes, they are easy prey to the owls.”
How it Works: Radiation Therapy and Natural Killer Cells
The research team investigated how cancer cells become resistant to radiation therapy. They discovered that radiation-resistant cells increase the production of proteins called “ligands” that are recognized by natural killer (NK) cells, a type of immune cell. This allows the immune system to identify and destroy the cancer cells. Essentially, the adaptations that allow cancer cells to survive radiation simultaneously make them more susceptible to NK cell-mediated killing, creating the “evolutionary double-bind.”
In laboratory experiments using multiple human prostate cancer cell lines, radiation-resistant cells were found to be up to twice as sensitive to NK cell killing compared to radiation-sensitive cells [2].
Challenging Conventional Cancer Biology
Professor Cliona O’Farrelly, Professor of Comparative Immunology at TCD, noted that this perform challenges the long-held assumption that resistance always comes at a cost to the cancer cell’s fitness. “Our work shows that even when resistant cells grow faster than sensitive ones, a double-bind strategy can still be effective if the second therapy preferentially targets the resistance itself,” she said.
Implications for Future Cancer Treatment
This research provides a blueprint for intentionally steering tumor evolution, rather than simply reacting to resistance after it emerges. It transforms evolutionary therapy from a conceptual idea into a testable, quantitative treatment design strategy. The Discipline of Radiation Therapy at Trinity College Dublin offers undergraduate and postgraduate programs, including a BSc. (Honours) degree in Radiation Therapy and a taught MSc. In Advanced Radiotherapy Practice [1], [2].
The findings are published in the International Journal of Radiation Oncology, Biology, Physics.